PURPOSE: Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network. PATIENTS AND METHODS: Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF). RESULTS: Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy. CONCLUSION: MIPI was prospectively validated in a large MCL patient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.

Eva Hoster Roswitha Forstpointner Wolfgang Hiddemann Martin H Dreyling and Michael Unterhalt University Hospital Munich; Eva Hoster University of Munich Munich; Wolfram Klapper University of Kiel; Christiane Pott University Hospital Schleswig Holstein Kiel; Michael Hallek Universität Köln Köln; Stephan Stilgenbauer University of Ulm Ulm Germany; Olivier Hermine University Paris Descartes and Université Sorbonne Paris Cité; Catherine Thieblemont Hôpital Saint Louis Paris; Vincent Ribrag Institut Gustave Roussy Villejuif France; Hanneke C Kluin Nelemans University of Groningen Groningen; Jeanette Doorduijn Erasmus MC Cancer Institute Rotterdam the Netherlands; Jan Walewski and Michal Szymczyk Maria Sklodowska Curie Memorial Institute Warsaw Poland; Achiel van Hoof A Z Sint Jan AV Brugge Belgium; Marek Trneny Charles University General Hospital Prague Czech Republic; Christian H Geisler Rigshospitalet Copenhagen Denmark; and Francesco Di Raimondo University of Catania Italy

References provided by Crossref.org

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic

Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases

See more in PubMed

ClinicalTrials.gov
NCT00209209, NCT00209222